Evidence map›Paper›PMID 30937878›Full record

ReviewDrugs & aging2019

Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Martin Klietz, Stephan Greten, Florian Wegner, Günter U Höglinger

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drugs & aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. When bad turns good: a systematic review on cholesterol and LDL in longitudinal patient cohorts with Parkinson's disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. The Treatment of Older Patients with Parkinson's Disease.Deutsches Arzteblatt international · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Active constituents of saffron (Experimental and therapeutic medicine · 2023
    Review
  17. Article
  18. Review
  19. Parkinson disease primer, part 2: management of motor and nonmotor symptoms.Canadian family physician Medecin de famille canadien · 2023
    Article
  20. Optimizing treatment for older adults with depression.Therapeutic advances in psychopharmacology · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Martin KlietzDepartment of Neurology, Hannover Medical School, Hannover, Germany. Klietz.Martin@mh-hannover.de.ORCID 0000-0002-3054-9905
Stephan GretenDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Florian WegnerDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Günter U HöglingerGerman Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
Medizinische Hochschule Hannover · DEGerman Center for Neurodegenerative Diseases · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease is a chronic neurodegenerative movement disorder affecting people mainly beyond their 50s. Geriatric patients with Parkinson's disease experience a specific profile of comorbidities. Multimorbidity and resulting polypharmacotherapy are frequent at this age. Comorbid diseases, widely spread, involve arterial hypertension, ischemic heart disease, heart failure, atrial fibrillation, polyneuropathy, diabetes mellitus, cerebrovascular disease, sarcopenia, and frailty. Following years of drug development, levodopa is still the most effective drug for the treatment of motor symptoms. However, a wide range of other drugs are available with specific effects, contraindications, and complications. The treatment of geriatric patients with Parkinson's disease is challenging and requires the cooperation of multidisciplinary teams. A careful assessment of a patient's Parkinson's disease symptoms, comorbidities, medication, vital signs, and resources is crucial for an effective and safe therapy. Laboratory tests can assist in the identification of contraindications for specific treatments. Identifying potentially inadequate drugs from prescription lists can lead to a better targeted treatment for geriatric patients with Parkinson's disease. Future research should help develop a more evidence-based therapy of geriatric patients with Parkinson's disease. For this purpose, randomized controlled trials of geriatric patients are urgently needed. An international register concerning issues of safer drug application and monitoring could help to implement a better treatment.

Indexed as

AgedAntiparkinson AgentsComorbidityDrug InteractionsHumansParkinson DiseasePolypharmacyAntiparkinson Agents

Identifiers

PMID30937878
OpenAlexW2930371867

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.